Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)

NCT03595657 is registered in ClinicalTrials.gov with CStone Pharmaceuticals as lead sponsor.

NCT NCT03595657
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03595657 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
Lead sponsor
CStone Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
June 12, 2018
Completion date
March 20, 2023
Enrollment
80 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal natural killer/t-cell lymphoma